Siemens Healthineers AG (Varian Medical Systems)
Siemens Healthineers is a global medical technology company that became a major force in the robotic radiotherapy market after its acquisition of Varian Medical Systems, Inc. in April 2021. Varian, a world leader in developing and manufacturing advanced radiotherapy equipment, including linear accelerators (LINACs) and proton therapy systems, forms the backbone of modern robotic radiotherapy. The company’s technology, such as the Novalis TX (a joint effort with BrainLAB) and the Ethos therapy system, leverages robotics and AI to deliver highly precise, image-guided, and adaptive radiation treatment. This integration ensures real-time adaptation to tumor movement, streamlining the workflow for daily treatment across various body sites. Siemens Healthineers’ commitment to substantial R&D investment ensures cutting-edge solutions like MR-LINACs, enabling precise tumor targeting and enhancing clinical outcomes, fulfilling their mission to build a world without cancer.
Latest Market Research Report on Robotic Radiotherapy Download PDF Brochure Now
Elekta AB
Elekta is a Swedish medical device company renowned for providing state-of-the-art solutions for cancer and brain disorders, with a significant presence in the robotic radiotherapy domain. Elekta offers a comprehensive portfolio including radiosurgery, radiation therapy systems, and clinical management software. Key products like the Elekta Synergy and the Leksell Gamma Knife are essential components of high-precision, non-invasive treatment. The company’s Synergy®S system uses an integrated high-resolution, multi-leaf collimator and advanced imaging for highly precise radiation delivery, capable of noncoplanar approaches. While the Gamma Knife is dedicated to stereotactic radiosurgery (a form of robotic-assisted treatment) for head and neck targets, the Axesse system is an image-guided robotic linac. Elekta continually strengthens its offerings, as demonstrated by its acquisition of Philips Healthcare’s Pinnacle Treatment Planning System portfolio, reinforcing its role in advancing treatment planning and delivery for complex radiation oncology cases.
Accuray Incorporated
Accuray is an American company, established in 1990, recognized globally for developing and manufacturing advanced radiation therapy systems. The company is a key player in robotic radiotherapy, widely known as the creator of the **CyberKnife® robotic radiosurgery system**. The CyberKnife system is a nonisocentric, image-guided robotic linear accelerator specifically designed for stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). This platform utilizes a robotic manipulator arm with six degrees of freedom to deliver radiation from thousands of unique angles with sub-millimeter precision. It features real-time tumor tracking and motion management, which is critical for treating mobile tumors in areas like the lung, prostate, and liver. Accuray also offers the TomoTherapy and Radixact systems. Its focus on innovative solutions, such as the all-in-one Accuray Stellar Solution, ensures precise, non-invasive, and adaptive treatment workflows, making it a visible leader in high-precision, robotic cancer care.
ViewRay Technologies, Inc.
ViewRay is an American company specializing in the development, manufacture, and marketing of a unique magnetic resonance imaging-guided radiation therapy (MR/RT) system. Their flagship product, the MRIdian® system, is a revolutionary robotic radiotherapy platform that integrates a high-field MRI scanner with a linear accelerator. This integration addresses a critical limitation of existing external radiation treatment by providing continuous, high-quality, soft-tissue visualization **during** the radiation delivery. This real-time imaging allows clinicians to see the tumor and surrounding organs at risk while the beam is on, enabling daily adaptive planning and precise beam gating to counteract intrafraction motion caused by breathing or organ shifts. The MRIdian system allows for the planning, production, and marketing of radiation treatment that can be adapted immediately, maximizing the dose to the tumor while minimizing exposure to healthy tissue. ViewRay’s technology represents a significant step forward in personalized and adaptive robotic radiation treatment.
IBA Worldwide (Ion Beam Applications)
IBA Worldwide, headquartered in Belgium, is a global leader in particle therapy, which is a key advanced technology within the broader field of robotic radiotherapy. The company is dedicated to developing and providing state-of-the-art proton therapy solutions for cancer treatment, which offer superior tumor targeting and reduced side effects compared to conventional photon therapy. IBA’s flagship systems, such as the ProteusONE™ and Proteus®PLUS, are integrated proton therapy platforms. These systems utilize advanced technology, including gantry and robotic patient positioning systems, to deliver highly focused proton beams with millimeter precision. The company’s Flexintensity™ system allows for personalized cancer treatment by modulating the beam’s intensity. As a major player in the particle therapy segment, IBA contributes to the robotic radiotherapy market by providing the infrastructure necessary for highly conformal and precise external beam radiation, often for challenging and sensitive tumors, accelerating the global adoption of this next-generation treatment modality.
Mevion Medical Systems
Mevion Medical Systems is an American company based in Littleton, Massachusetts, specializing in the provision of compact proton therapy systems for radiation therapy. Proton therapy, a type of particle therapy, is often considered a highly advanced form of external beam radiation within the robotic radiotherapy segment due to its superior dose conformity. Mevion is a main supplier of proton therapy frameworks, with their MEVION S250 Series® systems being the world’s only single-room, compact proton therapy solution. This compact design is a major market innovation, making proton therapy more accessible and affordable to a wider range of cancer treatment centers globally. The system is designed to provide pencil-beam scanning technology and offers highly precise and image-guided radiation delivery, which is essential for accurate tumor targeting. Mevion’s technology allows for a reduction in the size and cost of the required equipment, positioning it as one of the fastest-growing enterprises in the advanced radiotherapy market.
Hitachi Ltd.
Hitachi Ltd. is a long-standing Japanese multinational conglomerate with a significant presence in the medical devices sector, including the robotic radiotherapy market. As one of the segment’s founding members, Hitachi has been guiding the global medical industry for decades by offering world-class medical equipment. The company’s primary focus in this domain is on advanced particle therapy, specifically proton and heavy-ion beam therapy systems. These systems are highly advanced forms of external beam radiation that utilize sophisticated robotics and motion-tracking capabilities to deliver radiation with extreme precision, minimizing damage to surrounding healthy tissue. Hitachi’s continuous commitment to improving the quality of medical care is evidenced by its provision of advanced linear accelerators and CT simulators. By providing the essential infrastructure and technology for proton therapy, a highly precise treatment modality, Hitachi plays a key role in making complex, high-conformal radiation treatment accessible globally.
Brainlab AG
Brainlab AG is a German-based company that provides digital medical technology, playing a crucial role in enabling and enhancing robotic radiotherapy through its specialized software and hardware systems. The company’s core contribution is in the areas of image guidance, treatment planning, and patient positioning. Brainlab’s products, such as iPlan and ExacTrac, are integral to achieving the millimeter precision required by advanced stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) systems. ExacTrac is a high-precision X-ray and surface tracking system used to verify and monitor patient position and tumor location in real-time, ensuring that the radiation beam is delivered accurately, even with patient movement. The company has historically collaborated with major hardware manufacturers, such as with Varian (now Siemens Healthineers) on the Novalis TX system. Brainlab’s software and image-guidance solutions are key technological enablers that transform conventional LINACs into high-precision, robotic-assisted radiotherapy platforms.
RaySearch Laboratories AB
RaySearch Laboratories is a Swedish medical software company that is a major developer of advanced software solutions for radiation therapy. While not a manufacturer of the robotic hardware itself, RaySearch is a critical enabler of robotic radiotherapy through its innovative treatment planning systems. Their flagship product, **RayStation**, is an advanced, flexible treatment planning system that supports a comprehensive range of treatment delivery platforms, including robotic linear accelerators, Gamma Knife, and particle therapy systems. RayStation incorporates advanced tools such as adaptive radiation therapy and advanced planning algorithms, which are essential for maximizing the precision and efficiency of robotic systems. The company recently launched RayStation 12A, an advanced treatment radiation planning system. By providing sophisticated software that can optimize radiation delivery and manage the complexities of highly conformal treatments, RaySearch allows clinicians to fully utilize the robotic capabilities of modern linear accelerators, improving the quality and speed of personalized cancer treatment worldwide.
Panacea Medical Technologies Pvt. Ltd.
Panacea Medical Technologies, based in Bangalore, India, is a developer, producer, and supplier of healthcare services for radiotherapy and radiology equipment. As an innovation-driven organization, Panacea focuses on creating top-tier clinical hardware for cancer diagnosis and treatment, addressing the needs of modern radiotherapy. The company is involved in the robotic radiotherapy segment by producing and supplying equipment like advanced linear accelerators. Their mission is to improve existing radiotherapy services in a cost-effective manner, which is crucial for expanding the adoption of advanced treatment modalities, including robotic-assisted solutions, in emerging markets like Asia-Pacific. By developing and supplying high-quality, cost-effective equipment, Panacea plays an important role in making modern, precise cancer treatment more accessible, supporting the global trend toward sophisticated radiation delivery and improving patient outcomes in numerous regions.
Latest Market Research Report on Robotic Radiotherapy Download PDF Brochure Now